Aprea Therapeutics (APRE) Expected to Announce Earnings on Thursday

Aprea Therapeutics (NASDAQ:APRE) will likely be issuing its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Aprea Therapeutics to post earnings of ($0.11) per share for the quarter. Individuals can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, November 13, 2025 at 8:00 AM ET.

Aprea Therapeutics (NASDAQ:APRE) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.24. Aprea Therapeutics had a negative net margin of 1,645.01% and a negative return on equity of 78.90%. The firm had revenue of $0.12 million during the quarter. On average, analysts expect Aprea Therapeutics to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Aprea Therapeutics Stock Performance

NASDAQ:APRE opened at $1.40 on Tuesday. The company has a market cap of $8.16 million, a PE ratio of -0.60 and a beta of 1.30. The company has a 50 day simple moving average of $1.50 and a two-hundred day simple moving average of $1.64. Aprea Therapeutics has a 12 month low of $1.31 and a 12 month high of $5.00.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aprea Therapeutics in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $15.50.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.